Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.

Annals of laboratory medicine - 1 Mar 2020

Yoo Jaeeun, Lee Gun Dong, Kim Jee Hae, Lee Seung Nam, Chae Hyojin, Han Eunhee, Kim Yonggoo, Kim Myungshin

Abstract excerpt

BACKGROUND: Hereditary breast and ovarian cancer syndrome (HBOC) is caused by pathogenic variants in BRCA and other cancer-related genes. We analyzed variants in BRCA gene and other cancer-related genes in HBOC patients to evaluate the clinical validity of next-generation sequencing (NGS) multi-gene panel testing. METHODS: The BRCA1/2 NGS testing was conducted for 262 HBOC patients. Multiplex ligation-dependent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Checkpoint Kinase 2

Share to Fanconi Anemia Complementation Group N Protein

Share to Hereditary Breast and Ovarian Cancer Syndrome

Share to High-Throughput Nucleotide Sequencing

Share to Pedigree

Source

Open in PubMed Open full text

Identifiers

PMID: 31650731
DOI: 10.3343/alm.2020.40.2.148
PMCID: PMC6822011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.PMID 31650731Read ↗

Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test.Semantic proximity Read ↗

HBOC multi-gene panel testing: comparison of two sequencing centers.Semantic proximity Read ↗

Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.Semantic proximity Read ↗

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.Semantic proximity Read ↗

Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.Semantic proximity Read ↗

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?Semantic proximity Read ↗

Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer.Semantic proximity Read ↗

The results of multigene panel sequencing in Slovak HBOC families.Semantic proximity Read ↗

Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysisSemantic proximity Read ↗

Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.Semantic proximity Read ↗

Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2Semantic proximity Read ↗

Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.